| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $4.89B | +35.8% |
| Cost of Revenue | $1.07B | +33.8% |
| R&D Expense | $1.57B | +8.6% |
| SG&A Expense | $580.1M | +42.4% |
| Operating Income | -$1.23B | -15.9% |
| Pre-tax Income | -$1.07B | -14.0% |
| Income Tax | $3.6M | -12.7% |
| Net Income | -$1.07B | -13.9% |
| EPS (Basic) | -$1.54 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $1.21B | +69.4% |
| Short-term Investments | $1.85B | +9.0% |
| Accounts Receivable | $900.6M | +46.5% |
| Current Assets | $4.90B | +31.4% |
| Total Assets | $9.56B | +33.2% |
| Current Liabilities | $5.13B | +39.9% |
| Long-term Debt | $1.17B | -3.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $1.80B | +118.5% |
| Capital Expenditures | $441.0M | +145.5% |
| Investing Cash Flow | -$1.39B | -63.4% |
| Financing Cash Flow | $88.5M | +34.3% |
| Free Cash Flow | $1.36B | +110.9% |
| -6.9% |
| EPS (Diluted) | -$1.54 | -6.9% |
| Total Liabilities |
| $9.18B |
| +31.8% |
| Stockholders' Equity | $394.5M | +78.1% |